Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2017

View Archived Issues

Alyeyuba shows good preclinical results for the treatment of cutaneous leishmaniasis

Zafgen begins phase II study of ZGN-1061 in type 2 diabetes

Novel approach to develop tools for detection and monitoring of multiple neurodegenerative diseases

VAXIMM's oral T-cell immunotherapy granted orphan drug status in E.U.

Umecrine Cognition reports favorable results from phase Ib trial of GR-3027

Lef1 regulates hypothalamic neurogenesis and mediates anxiety in a wide variety of animal species

NIAID agrees to support phase I study of Geom Therapeutics' GT-1

Merger between Inspyr Therapeutics and Lewis and Clark Pharmaceuticals completed

First patient with DMD completes 15 months of treatment in Carmeseal-MD expanded access program

Preliminary phase I study of the third-generation EGFR inhibitor TAS-121 in NSCLC patients

First patient dosed in phase Ia study of OncoMed Pharmaceuticals' GITRL-Fc

Otonomy announces financial and business update

ND-L02-s0201 demonstrates efficacy in preclinical lung fibrosis models

FDA accepts for review the NDAs for binimetinib and encorafenib combination

Phase III ESSENCE study of SD-101 in epidermolysis bullosa does not meet primary endpoint

FDA grants orphan drug designation to Reata's omaveloxolone for malignant melanoma

Novel small conductance channel blockers presented by Acesion Pharma

FDA advisory committee recommends approval of Shingrix

AgeneBio wins grant to support GABA-A program for MCI due to Alzheimer's

Vanda reports phase II data on tradipitant in atopic dermatitis

Phase I results presented for resminostat/S-1 combination in pancreatic and biliary tract cancer

Alligator Bioscience enters 4-1BB research agreement with University of Navarra

FDA accepts for review sNDA for mirabegron in combination with solifenacin for overactive bladder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...